Alex has held a variety of editorial positions of increasing seniority on Scrip since joining the publication as a science reporter in 1998. Currently, she heads up the European editorial team coverage of commercial and R&D developments, while also writing news, analysis and features. Over the years, Alex has covered breakthroughs in R&D in a range of therapeutic areas, including infectious diseases, cardiology and cancer, and she enjoys interviewing key industry players and opinion leaders. Alex has a degree in Biochemistry and Microbiology from the University of Leeds and a keen interest in medical history.
Latest from Alexandra Shimmings
The data show promise for the investigational SERD as an adjuvant monotherapy, bringing it earlier in the treatment arc for ER-positive/HER2-negative early-stage breast cancer. The next major step for the product is preservERA.
While Amgen and Zai Labs await the results of a second Phase III trial before filing for approval, some hints as to what might have gone wrong for their FGFR2b-targeting monoclonal antibody in FORTITUDE-101 came with the full data presentation at ESMO this week.
Exelixis’s novel kinase inhibitor zanzalintinib has shown promise in a metastatic colorectal cancer population but some experts want to see more data before passing judgement on whether it can become a new chemotherapy-free treatment option for these patients.
The two TROP2-targeted antibody-drug conjugates have each shown promising data as first-line therapy in metastatic triple-negative breast cancer patients who are not candidates for PD-1/PD-L1 inhibitors.
The unprecedented results of DESTINY-Breast11 and DESTINY-Breast05 studies of AstraZeneca and Daiichi Sankyo’s blockbuster antibody-drug conjugate, Enhertu, point to it becoming the preferred treatment for many patients with high-risk early-stage HER2-positive breast cancer.
Roche is hopeful of getting a jump on its rivals by seeking a broad label for the oral SERD candidate, giredestrant, in advanced breast cancer on the back of significant efficacy in both all-comers and ESR1 mutant patients in the Phase III evERA study. Whether regulators will agree remains to be see